{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-029926","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.997268+00:00","generated_at":"2026-06-04T23:33:43.771246+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Heron Therapeutics Q4 2023: oncology revenue $107.9M, ZYNRELEF record $5.6M, 2024 guidance reaffirmed","bullets":["Full-year 2023 oncology care franchise revenue $107.9M exceeded guidance; net product sales up 11% YoY.","ZYNRELEF Q4 net product sales record $5.6M (up from $3.9M Q4 2022); acute care franchise sales $6.1M.","Gross margin improved to 71% in Q4 from 58% a year ago; cash and equivalents $80.4M at year-end.","FDA approved expanded ZYNRELEF label covering ~13M annual procedures; CrossLink partnership adds up to 650 sales reps.","2024 guidance: product revenues $138-158M, adjusted EBITDA $(22)-$3M; VAN program PAS submission on track for Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-029926","json":"https://secwatch.observer/filing/0000950170-24-029926.json","markdown":"https://secwatch.observer/filing/0000950170-24-029926.md","text":"https://secwatch.observer/filing/0000950170-24-029926.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017024029926/0000950170-24-029926-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017024029926/hrtx-20240312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:33:43.771246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8e5122497bb40b721ce469dfd412f951667cc77","claim":"HERON THERAPEUTICS, INC. /DE/ updated its the three and twelve months ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On March 12, 2024, Heron Therapeutics, Inc. (“Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023 (“Earnings Press Release”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017024029926/0000950170-24-029926-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and twelve months ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}